Abstract: A process for the determination of the presence or concentration of a polyepitopic antigen in a specimen, comprising contacting the specimen with a first reagent comprising one or more monoclonal antibodies to form a conjugate comprising monoclonal antibodies in the first reagent and an antigen in the specimen having epitopes to which said monoclonal antibodies are immunoreactive; contacting the conjugate so formed with a second reagent comprising one or more monoclonal antibodies to form a conjugate comprising the antigen, the monoclonal antibodies from the first reagent and the monoclonal antibodies from the second reagent, wherein one of the first and second reagents comprises two different monoclonal antibodies and the antibodies in the first reagent and the antibodies in the second reagent comprises three different monoclonal antibodies reactive with different epitopes on said antigen; and detecting the conjugate comprising the antigen and the three different monoclonal antibodies.

Abstract: The invention relates to a cornound having formula (I), wherein A, B, X, Y and r are as defined in the description, or a prodrug thereof or a pharnnaceutically acceptable salt thereof. The compounds of the invention have anticoagulant activity and can be used in treating or preventing thrombin-related diseases.

Abstract: A method and a test kit for genotyping the CCR5 chemokine receptor. CCR5 transcript DNA is amplified using transcription based amplification. The amplification product is detected through the hybridization of appropriately labeled oligonucleotide wild type and mutant probes. In a liquid hybridization based ECL analysis, the mutant probe is a 16mer having the sequence 5′TCCATACATTAAAGAT3′ [SEQ ID NO:9]. The method and kit can be used to predict.

Abstract: The invention relates to 20-aralkyl-5&agr;-pregnane derivative having general formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 is (H,OR), (H,OSO3H) or NOR; R is H, (C1-6)alkyl or (C1-6)acyl; each of R2 and R3 is independently hydrogen or (C1-6)alkyl; X is a straight chain divalent C1-8 hydrocarbon radical, optionally comprising a double or a triple bond; or X is —(CH2)m—CR7R8—; m=0-4; at least one of R7 and R8 is (C1-4)alkyl, hydroxy, (C1-4)alkoxy or halogen; the other, if present, being hydrogen; or R7 and R8 together represent O or NOR′; R′ is H, (C1-6)alkyl or (C1-6)acyl; each of R4, R5 and R6 is independently hydrogen, hydroxy, (C1-4)alkoxy, halogen, NR9, R10 or (C1-4)alkyl, optionally substituted by hydroxy, alkoxy, halogen or oxo; each of R9 and R10 is independently hydrogen or (C1-4)alkyl; and the dotted lines indicate a &Dgr;7 or a &Dgr;8 double bond, or a pair of conjugated double bonds selected from &Dgr;7,14, &Dgr;8,14 and

Abstract: The isolated human bone morphogenic protein-4 (BMP-4) promoter region, a vector comprising the isolated promoter region, and host cells comprising the isolated promoter region is described. A method for the identification of potential therapeutic agents for use in the prevention and/or treatment of osteoporosis, comprising the steps of: a) introducing into a cell a first expression vector comprising an isolated BMP-4 promoter region operably linked to a reporter gene, and a second expression vector comprising DNA encoding an estrogen receptor; b) contacting the cell with a candidate agent; and c) monitoring the expression of the protein encoded by the reporter gene, wherein induced expression of the protein indicates that the candidate compound is a potential therapeutic agent, is also described.

Abstract: This application relates to a combination of the antidepressant mirtazapine and an antipsychotic agent such as haloperidol for the treatment of psychotic disorders.

Abstract: The invention relates to a compound having the formula I ##STR1## wherein R.sup.1 is hydroxy, (1-6C)alkoxy or NR.sup.4 R.sup.5, R.sup.4 and R.sup.5 being independently hydrogen, (1-6C)alkyl, (3-7C)cycloalkyl, (2-6C)alkenyl, (4-6C)aryl or (5-7C)aralkyl, the aryl groups of which may be optionally substituted with halogen, (1-6C)alkyl or (1-6C)alkoxy;R.sup.2 is a halo atom, (1-8C)acyloxy, --O--C(O)--O-(1-6C)alkyl, --O--C(O)--O-(5-7C)aralkyl, --SR.sup.6, --S(O)R.sup.6, --SeR.sup.6 or --Se(O)R.sup.6, R.sup.6 being (1-6C)alkyl or (4-6C)aryl; andR.sup.3 is --Si(R.sup.7).sub.3, R.sup.7 being independently (1-6C)alkyl or (4-6C)aryl. The compounds of the invention may be used as protective groups or as linkers in solid phase organic chemistry.

Abstract: The invention relates to peptides or fragments thereof which are immunochemically reactive with Epstein-Barr Virus (EBV) antibodies. New antibodies directed to said peptides or fragments thereof are also part of the invention.

Abstract: The present invention is concerned with Infectious bursitis virus (IBDV) vaccines containing IBDV antigen material which is derived from a mammalian cell line infected with IBDV.

Abstract: Found is a pharmaceutical preparation which provides Tamoxifen Citrate in a liquid dosage form, viz. as an oral solution. The finding is based on a solvent comprising the following components: (a) of from 10% to 20% by weight of ethanol, (b) of from 10% to 60% by weight of a glycol; and (c) water, optionally containing additives, in a volume percentage adding up to 100% by volume. A preferred additive is sorbitol.

Abstract: For the oral administration of the anti-depressant mirtazapine an aqueous solution or suspension is found which is preferably stabilized by methionine, is thickened, and which has a pH of from 2.5 to 3. By the formulation according to the invention, an undesirable local anaesthetic effect of mirtazapine is avoided.

Abstract: The present invention relates to a novel bacterial respiratory poultry disease and the identification of the causative agent. A vaccine derived from this agent was effective in preventing the disease in chickens challenged with the virulent field strains.

Abstract: The present invention relates to a vaccine container that contains one or more freeze-dried vaccine components. The vaccine component or components are present in two or more freeze-dried bodies, at least one of which is a lyosphere.Furthermore, the invention relates to methods for the preparation of such a vaccine container.Also, the invention relates to a vaccine pack, comprising the vaccine container.

Abstract: This invention relates to Eimeria proteins with immunogenic properties as well as to DNA sequences encoding these proteins. These proteins can be administered to poultry thereby protecting the birds against coccidiosis. In addition the DNA encoding these proteins can be used for the preparation of a vector vaccine against coccidiosis.

Abstract: An isothermal transcription based amplification assay for MDC RNA uses primer combinations for sequences within the MDC gene. A quantitative control uses a mutant RNA for comparison.

Abstract: This invention relates to a novel infectious bronchitis virus (IBV) serotype and to attenuated IBV strains derived therefrom, and also to live or inactivated vaccines made using such IB virus. This invention also relates to a method for protecting poultry against IBV using these vaccines.

Abstract: The present invention relates to certain novel benzylamine derivatives, to processes for their preparation, to pharmaceutical formulations containing them and to their use in medical therapy, particularly in the treatment of depression.

Abstract: Disclosed is a process for the preparation of pharmaceutical dosage units containing as an active substance of from 0.005 to 1.0% by weight of micronised Org 30659, comprising (a) a mixing step comprising bringing into association the active substance and a suitable carrier to form a mixture, and (b) a granulating step in which the mixture is granulated to form agglomerates or granules by wetting the mixture with a binder liquid, the wetting being conducted under agitation, characterised in that the granulation step (b) is conducted so as to exert on the granules a shear force which does not exceed the tensile strength of the agglomerates or granules. The process leads to granules and tablets having an excellent content/uniformity.

Abstract: The invention relates to a microbial method of in vitro transformation of a steroid into its corresponding 11.alpha.-hydroxy analogue using oxygen and a microorganism selected from the Aspergillus ochraceus, Aspergillus niger, Rhizopus stolonifer, Rhizopus nigricans, Rhizopus arrhizus, and strains of Pestelotia, using as substrate a steroid having a purity of less than 97% and more than 90% at a concentration greater than 10 g/l.

Abstract: A method for determining whether an individual is at increased risk for thrombosis, comprising detecting the presence or absence of a genetic mutation located in the 3' untanslated region of the prothrombin gene (G to A mutation at position 20210) that is correlated with elevated prothrombin levels in individuals with the mutation, wherein the elevated prothrombin levels are associated with increased risk for thrombosis. Also provided are kits and primers that specifically hybridize adjacent to the region of the prothrombin gene that contains the G to A mutation at position 20210.